Martins-Green’s work centers on the sophisticated orchestration of chemokines, an essential group of signaling proteins that modulate inflammation, angiogenesis, and tissue regeneration. By meticulously dissecting the roles these molecules play during tissue injury, her laboratory has unraveled complex biological networks that govern the transition from damage to repair. These insights are critical because they address the persistent clinical dilemma where wounds fail to heal properly, often culminating in chronic, non-healing ulcers that burden patients and healthcare systems alike.

A watershed moment in her career came with the development of an innovative animal model. This model meticulously mimics human chronic wound conditions, offering a reliable platform for studying disease progression and therapeutic intervention. The model’s translational relevance has made it a gold standard within laboratories globally, catalyzing the development of new drug candidates and biomaterials aimed at accelerating tissue repair. Such preclinical tools are indispensable in bridging laboratory findings with clinical applications, expediting the path from bench to bedside.

What distinguishes Martins-Green’s approach is her commitment to precision and clinical relevance. She has extended her foundational research into ongoing clinical trials, notably collaborative efforts in Europe that seek to enhance the efficacy of treatments for chronic wounds. These trials embody a precision medicine ethos, tailoring interventions based on mechanistic insights derived from her lab’s work. By integrating molecular biology with patient-centered outcomes, her team exemplifies a multidisciplinary strategy essential for addressing complex diseases.

Beyond trauma and wound healing, Martins-Green’s research portfolio encompasses the profound effects of environmental toxins, particularly tobacco smoke, on tissue integrity. Her investigations have unveiled the molecular pathways by which smoke toxins disrupt cellular homeostasis, exacerbate inflammation, and impair regenerative capacities. This line of inquiry has had far-reaching implications, influencing public health policies and legislative measures aimed at reducing tobacco-related harm. Such impact underscores her research’s societal significance, transcending academic boundaries.

The breadth of Martins-Green’s academic contributions is reflected in her prolific publication record, which exceeds 150 peer-reviewed articles, alongside her ownership of two patents. These patents highlight her innovative capacity to translate basic research into potential therapeutic tools. Her scholarship has garnered widespread recognition, from prestigious awards to fellowships, including election as a fellow of both the American Association for the Advancement of Science (AAAS) and the Wound Healing Society (WHS).

Her journey, marked by international academic experiences and mentorship, started in Portugal, where she earned her undergraduate degree before advancing to a doctorate in zoology at UC Davis. Following rigorous postdoctoral training at Lawrence Berkeley National Laboratory and faculty appointments across esteemed institutions, she joined UCR’s faculty in 1993. Over more than three decades, she has maintained a steadfast commitment to education, mentoring a diverse body of students who have themselves ascended to prominent roles in science and medicine.

Martins-Green’s pedagogical philosophy emphasizes fostering critical thinking and experimental rigor. She encourages students to approach scientific questions with curiosity and intellectual discipline—skills that are indispensable for the next generation of researchers. This mentorship has been transformative for many protégés, who attest to her ability to inspire and empower through both guidance and genuine personal investment.

Her leadership extends beyond the laboratory and classroom, having chaired departmental and university academic bodies, as well as contributing to editorial activities within scientific journals. Her service reflects a dedication to shaping research agendas, supporting peer review processes, and enhancing scientific communication—cornerstones for advancing the collective knowledge base in cell biology and regenerative medicine.

The forthcoming 2026 Lifetime Achievement Award from the Wound Healing Society is a testament to Martins-Green’s enduring impact on the field. This honor, bestowed on individuals who have significantly propelled wound healing research and patient care, recognizes not just scientific discoveries but also leadership and mentorship. It cements her legacy as a luminary whose work embodies the intersection of scientific innovation, clinical relevance, and compassionate dedication.

As the scientific community gathers in Charlotte, North Carolina, to celebrate her accomplishments, Martins-Green remains humble, attributing much of her success to the collaborative spirit of her laboratory team and the unwavering support of her family. Her story exemplifies how scientific excellence thrives within a network of mentorship, partnership, and resilience.

In sum, Manuela Martins-Green’s career journey is emblematic of the profound influence that dedicated research can wield on human health. By unraveling the molecular choreography of wound healing and pioneering models that simulate human disease, she has significantly advanced the understanding and treatment of chronic wounds. Her work continues to inspire innovation, nurture the next generation of scientists, and inform public health—hallmarks of a true scientific trailblazer.

Subject of Research:
Cellular and molecular mechanisms of wound healing, chemokine signaling in inflammation and angiogenesis, chronic wound pathophysiology, and effects of environmental toxins on tissue repair.

Article Title:
Leading the Charge in Wound Healing: Manuela Martins-Green’s Pioneering Contributions to Regenerative Medicine

News Publication Date:
2024

Web References:

• https://profiles.ucr.edu/app/home/profile/mmgreen
• https://woundheal.org/

Image Credits:
Credit: UC Riverside

Keywords

Wound healing, chemokines, chronic wounds, tissue engineering, angiogenesis, tobacco smoke toxins, molecular biology, regenerative medicine, clinical trials, cellular biology, inflammation, Manuela Martins-Green

Their groundbreaking study focuses on anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare and often debilitating autoimmune condition characterized by inflammation that damages small blood vessels, potentially compromising vital organ function. Despite the clinical significance of ANCA-associated vasculitis, the heterogeneity of its pathogenesis has long impeded the development of targeted therapies. This research illuminates the cellular mechanisms underpinning the disease, highlighting the dynamic roles neutrophils play beyond the traditional paradigm.

The research team employed high-resolution single-cell transcriptomics and proteomics to analyze approximately 180,000 white blood cells extracted from a cohort comprising six patients newly diagnosed with ANCA-associated vasculitis and seven healthy controls. This dual-layered approach, examining both gene expression profiles and surface protein markers, enabled the identification of distinct neutrophil subsets and an in-depth characterization of their functional states. By meticulously scrutinizing the cellular data, the team detected a pronounced expansion of two specific neutrophil subpopulations exclusively present in the patient samples.

Among these neutrophil subsets was one notably sensitive to interferon-gamma (IFN-γ), a cytokine critical for immune modulation and inflammatory responses. This IFN-γ-responsive neutrophil population exhibited high activatability, suggesting a hyperinflammatory phenotype. Detailed gene expression analysis revealed these cells upregulated multiple interferon-stimulated genes, emblematic of heightened immune activation. The presence of this subset strongly correlated with disease persistence and treatment resistance, marking it as a potential biomarker for aggressive vasculitis phenotypes.

Senior author Atsushi Kumanogoh emphasized the clinical relevance of discovering such a subset, stating that this population’s abundance predicted continued disease activity despite conventional interventions. This finding augments previous understandings by associating specific immune cell behaviors with clinical outcomes, thereby paving the way for precision medicine approaches tailored to individual immunological profiles. The ability to predict disease relapse early in the disease course could profoundly impact patient management strategies.

To validate the clinical implications of their cellular findings, the team measured serum IFN-γ concentrations in a broader pool of patients, including both newly diagnosed and previously treated individuals. Their analysis showed that among 24 patients at disease onset, the six with the highest circulating IFN-γ levels were all prone to disease relapse. This compelling evidence points to IFN-γ not only as a marker of neutrophil activation but also as an accessible plasma biomarker for forecasting vasculitis course.

The technical prowess of this study demonstrates the utility of integrating single-cell RNA sequencing with proteomic profiling to unravel complex immune heterogeneity. By dissecting neutrophils at the single-cell level, researchers could disentangle the nuanced functional diversity previously masked in bulk analyses. This has profound implications for the field of immunology, highlighting the necessity of high-resolution approaches to understand immune-mediated diseases’ intricate cellular networks.

Moreover, this research contributes to the evolving narrative that immune dysregulation in autoimmune diseases is multifaceted, involving discrete immune cell populations driving pathogenic processes. The identification of an IFN-γ-associated neutrophil subset extends the conceptual framework beyond mere neutrophil activation to a more refined model involving cytokine-mediated modulation of specific myeloid lineages. Such insights are instrumental in conceptualizing novel therapies designed to disrupt these pathogenic interactions selectively.

From a therapeutic standpoint, targeting IFN-γ signaling pathways or the identified neutrophil subsets could revolutionize treatment paradigms for ANCA-associated vasculitis. Current therapies often involve broad immunosuppression, which can compromise host defenses and result in significant side effects. By contrast, interventions tailored to modulate these high-activability neutrophils might achieve disease remission more effectively while minimizing systemic immunosuppression risks.

Furthermore, this study underscores the value of longitudinal immunomonitoring in autoimmune diseases. The ability to track neutrophil subpopulation dynamics and IFN-γ serum levels over time could refine prognostic models and inform therapeutic adjustments. This would empower clinicians with actionable biomarkers to anticipate relapse, optimize treatment intensity, and ultimately enhance patient quality of life.

Beyond its immediate clinical implications, the research epitomizes how collaborative, multi-institutional efforts can harness cutting-edge methodologies to address unmet medical needs. By recruiting untreated, newly diagnosed patients, the team captured early disease immunopathology, providing a pristine snapshot of disease onset free from confounding treatment effects. This strategic cohort selection bolsters the study’s robustness and translational potential.

In sum, the discovery of a type II interferon-related neutrophil subset predictive of autoimmune vasculitis relapse marks a significant stride forward in immunology and clinical medicine. It not only provides mechanistic clarity but also offers tangible pathways toward personalized medicine. As this knowledge is integrated into clinical practice, patients suffering from this challenging disease may anticipate more precise diagnostics and targeted therapeutics tailored to their unique immune landscapes.

The study titled "Neutrophil single-cell analysis identifies a type II interferon-related subset for predicting relapse of autoimmune small vessel vasculitis," will be published in Nature Communications, reflecting a milestone in the quest to decode autoimmune vasculitis. This research not only advances our understanding of neutrophil heterogeneity but also illustrates the transformative impact of single-cell technologies in unraveling complex human diseases.

For scientists, clinicians, and patients alike, these insights herald a new era in combating autoimmune disorders, one that leverages the power of cellular resolution to tailor interventions and improve outcomes. Continued exploration of neutrophil biology and cytokine interactions promises to unlock further therapeutic targets, underscoring the remarkable potential of immunology’s next frontier.

Subject of Research: Human tissue samples

Article Title: Neutrophil single-cell analysis identifies a type II interferon-related subset for predicting relapse of autoimmune small vessel vasculitis

News Publication Date: 24-Apr-2025

Web References: http://dx.doi.org/10.1038/s41467-025-58550-7

Image Credits: Masayuki Nishide

Keywords: Health and medicine, Vascular diseases, Autoimmune disorders, Interferons, Neutrophils, Myeloid cells